Results 81 to 90 of about 19,810 (255)

The Current Role of Peptide Receptor Radionuclide Therapy in Meningiomas

Journal of Clinical Medicine, 2022
Meningiomas are the most common primary intracranial tumors. The majority of patients can be cured by surgery, or tumor growth can be stabilized by radiation. However, the management of recurrent and more aggressive tumors remains difficult because no established alternative treatment options exist.
Christina-Katharina Fodi, Jens Schittenhelm, Jürgen Honegger, Salvador Guillermo Castaneda-Vega, Felix Behling   +4 more
openaire   +2 more sources

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate [PDF]

, 2009
Adequate dosimetry is mandatory for effective and safe peptide receptor radionuclide therapy (PRRT). Besides the kidneys, the bone marrow is a potentially dose-limiting organ.
Flavio Forrer, Eric P. Krenning, Peter P. Kooij, Bert F. Bernard, Mark Konijnenberg, Willem H. Bakker, Jaap J. M. Teunissen, Marion de Jong, Kirsten van Lom, Wouter W. de Herder, Dik J. Kwekkeboom   +10 more
core   +1 more source

Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review [PDF]

, 2021
Baptiste Camus, Anne‐Ségolène Cottereau, Lola‐Jade Palmieri, Solène Dermine, Florence Tenenbaum, Catherine Brézault, Romain Coriat   +6 more
openalex   +1 more source

Peptide receptor radionuclide therapy for metastatic paragangliomas

Medical Oncology, 2016
There is little evidence to direct the management of malignant paragangliomas (mPGL) beyond initial surgical treatment. Peptide receptor radionuclide therapy (PRRT), using somatostatin analogues, is effective in other neuroendocrine tumours, but data on its efficacy in treating mPGL are scarce.
Pinato D. J., Black J. R. M., Ramaswami R., Tan T. M., Adjogatse D., Sharma R.   +5 more
openaire   +4 more sources

Carbon Dots for Cancer Theranostics: Synthesis Strategies, Luminescence Properties, and Advances in Bioimaging‐Guided Diagnosis and Therapy

Chemistry – A European Journal, EarlyView.
Lighting up the path to precision oncology: This review comprehensively summarizes the rational design of carbon dots (CDs), elucidating how core size, surface chemistry, and heteroatom doping dictate their luminescence mechanisms. Special emphasis is placed on engineering NIR‐II emissive CDs for deep‐tissue imaging.
Zekun Yan, Yupeng Liu, Jinyun Tan, Songnan Qu   +3 more
wiley   +1 more source

Towards a Radio-guided Surgery with $\beta^{-}$ Decays: Uptake of a somatostatin analogue (DOTATOC) in Meningioma and High Grade Glioma

, 2014
A novel radio guided surgery (RGS) technique for cerebral tumors using $\beta^{-}$ radiation is being developed. Checking the availability of a radio-tracer that can deliver a $\beta^{-}$ emitter to the tumor is a fundamental step in the deployment of ...
BELLINI, Fabio, Bocci, Valerio, Chiodi, Giacomo, COLLAMATI, FRANCESCO, Cremonesi, Marta, DE LUCIA, Erika, FACCINI, Riccardo, Ferrari, Mahila E., Frallicciardi, Paola M., Grana, Chiara M., Marafini, Michela, Mattei, Ilaria, Morganti, Silvio, PATERA, Vincenzo, PEPE, ALESSANDRA, PIERSANTI, LUCA, PINCI, davide, Recchia, Luigi, RUSSOMANDO, ANDREA, SARTI, ALESSIO, SCIUBBA, Adalberto, SENZACQUA, MARTINA, SOLFAROLI CAMILLOCCI, ELENA, VOENA, Cecilia   +23 more
core   +1 more source

Phosphorescent Iridium Hydrazinonicotinic Acid (HYNIC) Complexes That Bind to Prostate Specific Membrane Antigen: Potential Photodynamic Therapy of Prostate Cancer

Chemistry – A European Journal, EarlyView.
A phosphorescent iridium(III) complex has been prepared with a 6‐hydrazinonicotinic acid (HYNIC) ligand tethered to a lysine‐ureido‐glutamatic acid pharmacophore, which binds to an enzyme, called prostate‐specific membrane antigen (PSMA), which is overexpressed in prostate cancer.
La'El Kimchi, Emily R. McGowan, Katherine A. Morgan, Jonathan M. White, Trevor A. Smith, Stacey E. Rudd, Paul S. Donnelly   +6 more
wiley   +1 more source

Novel small peptides derived from VEGF125-136: potential drugs for radioactive diagnosis and therapy in A549 tumor-bearing nude mice

Scientific Reports, 2017
Vascular endothelial growth factor receptor (VEGFR) is a critical factor in tumor angiogenesis and has been considered a potential target for receptor-mediated radionuclide imaging and therapy.
Xiang Zhang, Shibin Feng, Jie Liu, Qianwei Li, Lei Zheng, Laiping Xie, Hongmin Li, Dingde Huang   +7 more
doaj   +1 more source

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr 3]octreotate [PDF]

, 2008
Introduction: Receptor radionuclide therapy is a promising treatment modality for patients with neuroendocrine tumors for whom alternative treatments are limited.
Aken, M.O. (Maarten) van, Essen, M. (Martijn) van, Feelders, R.A. (Richard), Herder, W.W. (Wouter) de, Kam, B.L. (Boen), Keizer, B. (Bart) de, Krenning, E.P. (Eric), Kwekkeboom, D. (Dik)   +7 more
core   +1 more source